Trends and Patterns of Medical Stimulant Use by US Adults

Why It Matters

The surge in stimulant use strains supply chains and raises public‑health concerns about misuse, prompting regulators and insurers to reassess prescribing safeguards.

Key Takeaways

• Stimulant prescriptions rose 30% from 2013 to 2022.
• Telehealth accounted for 40% of new adult ADHD starts.
• FDA reported nationwide Adderall and methylphenidate shortages in 2025.
• Misuse prevalence highest among males and low‑income adults.
• Prescribing patterns vary by state and specialist type.

Pulse Analysis

The past decade has seen adult attention‑deficit/hyperactivity disorder (ADHD) transition from a niche diagnosis to a mainstream medical concern. Growing awareness of adult ADHD, coupled with broader insurance coverage, has driven clinicians to prescribe central nervous system stimulants more frequently. Telemedicine, accelerated by pandemic‑era policy flexibilities, now facilitates rapid assessment and prescription, accounting for roughly four‑in‑ten new stimulant starts among adults. This shift not only expands access for underserved populations but also reshapes prescribing workflows, prompting health systems to integrate digital screening tools and remote monitoring protocols.

Supply chain volatility has emerged as a parallel challenge. In 2025 the FDA issued alerts about nationwide shortages of Adderall and extended‑release methylphenidate, reflecting heightened demand and manufacturing bottlenecks. Patients facing interruptions risk symptom relapse, increased emergency‑room visits, and potential off‑label substitution. Regulators have responded with expedited approval pathways for alternative formulations and tighter inventory reporting requirements. Insurers, meanwhile, are revisiting prior‑authorization criteria to balance continuity of care with stewardship of controlled substances.

Beyond access, the data expose a concerning misuse gradient. Men and individuals in lower socioeconomic brackets exhibit disproportionately higher rates of non‑medical stimulant use, echoing broader substance‑use disparities. State‑level analyses reveal that prescribing intensity correlates with specialist density and local policy environments, suggesting that targeted education and prescribing guidelines could mitigate over‑prescription. As telehealth solidifies its role, policymakers must align digital prescribing standards with robust risk‑assessment frameworks to safeguard public health while preserving the therapeutic gains for adults managing ADHD.